Despite tremendous progress in our understanding of cancer biology, most novel anticancer therapies fail in Phase 3 clinical trials. This situation brings into question the quality of preclinical tumor models and predictability of preclinical trials. Selection of appropriate animal models based on similarity to human biology/ tumor heterogeneity carries considerable potential to ensure a higher predictability of preclinical trials.
Cambridge Healthtech Institute’s Tumor Models to Guide Targeted Cancer Therapy and Drug Development conference aims to bring together cancer researchers and clinicians working on development of molecularly targeted cancer therapies, and to initiate a knowledge exchange around preclinical models and their optimization. Highly characterized patient-derived tumor tissue xenograft models that allow us to more effectively evaluate novel targeted therapeutics as well as to identify predictive biomarkers in early stages of drug development will be discussed. Case studies and solutions for increasing the reproducibility and predictability of preclinical cancer studies will be presented.
Coverage will include, but will not be limited to:
- Co-clinical trials
- Predictive biomarker identification in murine models
- PDX tumor banks
- Modeling inter-patient response heterogeneity using PDX models
- Genomic analyses in support of preclinical cancer research
- Imaging and pathology confirmation of treatment response
- Orthotopic tumor models
- Phenotypic screening with PDX models
- PDX models for cancer stem cell research
- Optimizing technology of patient-derived xenograft animal models
- Metastatic animal models of cancer
- Preclinical studies that involve combination cancer therapy
- Modeling primary and resistant tumors
- Mouse trials: following human clinical trial approaches
- Exploring the possible combination of targeted therapy and immunotherapy
- Solutions for increasing reproducibility of data
- Validation of animal models
- Industry-academia collaboration in the area of preclinical models in oncology
Scientists who wish to present their knowledge and expertise to their colleagues are asked to submit an abstract.
Click here to submit a speaking proposal. Remember to specify the conference that you are interested in and please provide your full contact information.
Visit www.worldpharmacongress.com to register for a very special early-bird discounted rate.
The deadline for submission is November 1, 2013.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, please contact:
Marina Filshtinsky, M.D.
Cambridge Healthtech Institute
T: (+)781.972.5455, E: email@example.com
For partnering & sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431, E: firstname.lastname@example.org